NCT01987999
Completed
Phase 2
Phase II Eradication of Prostate Cancer Using F-989
Optimal Health Research0 sites60 target enrollmentFebruary 2013
ConditionsProstate Cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- Optimal Health Research
- Enrollment
- 60
- Primary Endpoint
- Gleason Score
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The purpose of this study is to confirm the findings of an early study with prostate cancer and to expand our knowledge of treating prostate cancer using F-989.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Clinical diagnosis of prostate cancer
- •Referred to the study by their treating physician
Exclusion Criteria
- •Any type of treatment before starting study
Outcomes
Primary Outcomes
Gleason Score
Time Frame: 1 year
A Gleason Score is obtained from the results of a transrectal needle biopsy of the prostate.
Secondary Outcomes
- Prostate Specific Antigens (PSA)(1 year)
Similar Trials
Terminated
Phase 2
Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical ProstatectomyProstatic NeoplasmsNCT02772562Medical University of South Carolina33
Recruiting
Phase 2
TERPS Trial for de Novo Oligometastic Prostate CancerProstate CancerOligometastatic DiseaseNCT05223803University of Maryland, Baltimore122
Active, not recruiting
Phase 2
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery EmbolizationProstate CarcinomaBenign Prostatic HyperplasiaNCT04879940H. Lee Moffitt Cancer Center and Research Institute17
Completed
Phase 2
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging TherapiesMetastatic Castration-resistant Prostate CancerNCT04158245Tulane University9
Completed
Phase 1
Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission TomographyProstate CancerNCT01310192Queen's Medical Center20